Banner
Late-Breaking Analysis In Hypertension Shows That Antihypertensive Treatments Differ In Their Ability To Preserve Lives

STOCKHOLM, August 30, 2010 /PRNewswire/ -- According to the results of a late-breaking analysis...

Clinical Results For New Treatment Of Bacterial Vaginosis Infection

The Swedish company Laccure AB recently got CE marking as a Class IIa medical device product for...

88 Percent Of UK Doctors Believe Whiplash Claims Are Exaggerated

AXA, a UK car insurer, has surveyed UK doctors as part of its ongoing campaign to understand the...

On Facebook, Women Are More Plentiful But Men Are Better Ad Targets

Global digital marketing companies Resolution Media and Kenshoo Social published a new report today...

User picture.
Anna OhldenRSS Feed of this column.

Media Relations Executive, PR Newswire Europe... Read More »

Blogroll

FAREHAM, England, February 27 /PRNewswire/ --

- Acquisition Allows Users to Expand Their Base of Friends and Use New Mobile Features

3BILL has today announced that it has acquired a UK Social Networking Platform aimed at 15-24 years olds. The company has not disclosed terms of the purchase for the site http://www.profileheaven.com - winner of 2006 UK Website of the Year - Best Community Site.

PERTH, Australia, February 27 /PRNewswire/ --

Nido Petroleum Ltd (Nido) is pleased to announce that the Galoc 3 horizontal production well flowed oil to the surface unassisted at a maximum rate of 5,397 barrels per day during clean up flow testing on 20 and 21 February 2008.

The purpose of the Galoc 3 clean up and oil flow to surface was to confirm the integrity of the well and installed completion equipment as well as to ascertain the well's ability to flow.

Pressure, temperature and flow rate data were recorded on surface and on subsurface gauges located down-hole, close to the reservoir. Oil samples were also collected and will be sent to a specialist laboratory for assay and PVT analysis.

UXBRIDGE, England, February 27 /PRNewswire/ -- Otsuka Pharmaceutical Europe Ltd. (OPEL) announced today that the European Medicines Agency (EMEA) has accepted a marketing authorisation application (MAA) for the company's investigational oral once-daily medication tolvaptan, a selective V2-vasopressin receptor antagonist, for the treatment of worsening heart failure and the treatment of hyponatraemia. (1) These indications are based on data from two separate clinical development programmes.(2),(3),(4)

COPEHNAGEN, Denmark, February 26 /PRNewswire/ --

- Genmab Announced Today the Purchase Agreement Entered Into Between Genmab and PDL BioPharma Under Which Genmab Would Acquire PDL's Manufacturing Facility has Received Antitrust Clearance.

PARIS, February 26 /PRNewswire/ -- With a 40% increase in software sales, a tripling of results, and a profitability of over 20%, SynerTrade, a specialist in consultancy and producer of Purchasing Function software solutions, announces a record 2007 fiscal year.

2007 has been the best financial year in SynerTrade's history to date since the creation of the two original companies, SynerDeal and Trade2B. "2007 results have tripled compared to the previous financial year and we foresee a 40% increase in the number of orders for the new financial year", says Eberhard Aust, SynerTrade's Chief Executive Officer.

TOULOUSE, France and SANTA CLARA, California, February 26 /PRNewswire/ --

Intexys Photonics introduces its family of Optical Engines for parallel optics applications and more particularly for the Optical Active Cable emerging market.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070905/AQW066LOGO )

The Optical Engine Family consists of a (4+4) x5Gbit/s Infiniband compliant engine and a QSFP version just released. The family will also include a (4+4) x10Gbit/s engine in March with a 12x10Gbs engine in late 2008.